Mara Goldstein
Stock Analyst at Mizuho
(2.77)
# 1,917
Out of 4,711 analysts
74
Total ratings
43.4%
Success rate
7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $7 → $9 | $4.19 | +114.80% | 6 | Dec 19, 2024 | |
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $9.01 | +255.16% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $15.50 | +170.97% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $24.13 | +107.21% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $13.08 | +244.04% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $68.84 | +11.85% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.54 | +175.59% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.68 | +376.19% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $2.91 | +312.37% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $7.38 | +306.50% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.93 | +546.34% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $4.99 | -29.86% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.25 | +4,723.15% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $2.00 | +900.00% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $98.05 | +32.59% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.09 | +83.49% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.29 | +424.02% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.60 | +1,387.85% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $48.87 | -59.08% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $5.63 | +752.58% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.14 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $4.82 | +190.46% | 1 | Oct 12, 2017 |
Verastem
Dec 19, 2024
Maintains: Outperform
Price Target: $7 → $9
Current: $4.19
Upside: +114.80%
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $9.01
Upside: +255.16%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $15.50
Upside: +170.97%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $24.13
Upside: +107.21%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.08
Upside: +244.04%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $68.84
Upside: +11.85%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.54
Upside: +175.59%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.68
Upside: +376.19%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $2.91
Upside: +312.37%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $7.38
Upside: +306.50%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.93
Upside: +546.34%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $4.99
Upside: -29.86%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.25
Upside: +4,723.15%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $2.00
Upside: +900.00%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $98.05
Upside: +32.59%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.09
Upside: +83.49%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.29
Upside: +424.02%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.60
Upside: +1,387.85%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $48.87
Upside: -59.08%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $5.63
Upside: +752.58%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $25.14
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $4.82
Upside: +190.46%